<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950937</url>
  </required_header>
  <id_info>
    <org_study_id>06067</org_study_id>
    <nct_id>NCT00950937</nct_id>
  </id_info>
  <brief_title>Exercise, Oxidative Stress and HIV</brief_title>
  <official_title>A Case-control Study to Test the Effects of a Bout of Aerobic Exercise Followed by Resistance Training on Antioxidant System in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare oxidative stress markers and the immunologic
      characteristics of HIV-infected and non-HIV subjects during a bout of moderate aerobic
      exercise followed by resistance exercises
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total Glutathione</measure>
    <time_frame>3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catalase Activity</measure>
    <time_frame>3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutathione S-transferase (GST)</measure>
    <time_frame>3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Peroxidation</measure>
    <time_frame>3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T CD4</measure>
    <time_frame>3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil Count</measure>
    <time_frame>3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Oxygen Uptake</measure>
    <time_frame>1 time, before the exercise protocol</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">28</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV Group</arm_group_label>
    <description>HIV infected persons</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Non HIV-infected persons</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The participants of the HIV group were recruited at the outpatient HIV/AIDS care unit of
        the Hospital de Clínicas de Porto Alegre (HCPA), whereas the control group (non-HIV) was
        formed by volunteers of the city of Porto Alegre, Rio Grande do Sul, Brazil
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV Group:without contraindications for exercise training; to highly active
             antiretroviral therapy (HAART) for at least 6 months before enrollment; be classified
             as low level of physical activity by international physical activity questionnaire
             (IPAQ) and did not use antioxidant supplements.

          -  Control Group:negative result for HIV-1 test and the other criteria described above

        Exclusion Criteria:

          -  Subjects with previous history of cardiovascular and neurological disease, diabetes,
             dyslipidemia, tobacco using, physical disability and pregnant women were excluded from
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Dall'Ago, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas de Porto Alegre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Outpatient HIV/AIDS care unit of the Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2009</study_first_posted>
  <results_first_submitted>February 16, 2009</results_first_submitted>
  <results_first_submitted_qc>June 25, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2009</results_first_posted>
  <last_update_submitted>August 4, 2009</last_update_submitted>
  <last_update_submitted_qc>August 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pedro Dall'Ago</name_title>
    <organization>Hospital de Clinicas de Porto Alegre</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HIV Group</title>
          <description>HIV infected persons</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Non HIV-infected persons</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIV Group</title>
          <description>HIV infected persons</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Non HIV-infected persons</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.2" spread="8.7"/>
                    <measurement group_id="B2" value="36" spread="10.6"/>
                    <measurement group_id="B3" value="37.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Catalase Activity</title>
        <description>Antioxidant activity of the catalase enzyme at three moments: baseline, aerobic and exercise.</description>
        <time_frame>3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Group</title>
            <description>HIV infected persons</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Non HIV-infected persons</description>
          </group>
        </group_list>
        <measure>
          <title>Catalase Activity</title>
          <description>Antioxidant activity of the catalase enzyme at three moments: baseline, aerobic and exercise.</description>
          <units>units of catalase /mg protein</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.578" lower_limit="0.049" upper_limit="1.338"/>
                    <measurement group_id="O2" value="0.967" lower_limit="0.312" upper_limit="2.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aerobic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.316" upper_limit="2.598"/>
                    <measurement group_id="O2" value="0.855" lower_limit="0.087" upper_limit="1.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.566" lower_limit="0.317" upper_limit="3.510"/>
                    <measurement group_id="O2" value="1.009" lower_limit="0.333" upper_limit="2.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon test was utilized to compare the three moments: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman Test</method>
            <method_desc>Friedman to compare: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance. Wilcoxon was applied to locate the differences</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman Test</method>
            <method_desc>Friedman to compare: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance. Wilcoxon was applied to locate the differences</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Glutathione</title>
        <description>The total glutathione content in erythrocyte concentrate at three moments: baseline, aerobic and resistance exercise.</description>
        <time_frame>3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Group</title>
            <description>HIV infected persons</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Non HIV-infected persons</description>
          </group>
        </group_list>
        <measure>
          <title>Total Glutathione</title>
          <description>The total glutathione content in erythrocyte concentrate at three moments: baseline, aerobic and resistance exercise.</description>
          <units>nmoles glutathione/ ml of sample</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1,964" lower_limit="319" upper_limit="2,577"/>
                    <measurement group_id="O2" value="3,490" lower_limit="597" upper_limit="7,596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aerobic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1,865" lower_limit="780" upper_limit="5,006"/>
                    <measurement group_id="O2" value="3,995" lower_limit="2,308" upper_limit="6,068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1,767" lower_limit="516" upper_limit="2,420"/>
                    <measurement group_id="O2" value="3,206" lower_limit="2,456" upper_limit="7,202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon test was utilized to compare the three moments: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman Test</method>
            <method_desc>Friedman to compare: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance. Wilcoxon was applied to locate the differences</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman Test</method>
            <method_desc>Friedman to compare: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance. Wilcoxon was applied to locate the differences</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glutathione S-transferase (GST)</title>
        <description>Antioxidant activity of the Glutathione S-transferase enzyme at three moments: baseline, aerobic and resistance exercise.</description>
        <time_frame>3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Group</title>
            <description>HIV infected persons</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Non HIV-infected persons</description>
          </group>
        </group_list>
        <measure>
          <title>Glutathione S-transferase (GST)</title>
          <description>Antioxidant activity of the Glutathione S-transferase enzyme at three moments: baseline, aerobic and resistance exercise.</description>
          <units>micromol of GST/min/mg of protein</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" lower_limit="0.18" upper_limit="0.58"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.42" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aerobic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" lower_limit="0.09" upper_limit="0.42"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.34" upper_limit="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="0.31" upper_limit="0.63"/>
                    <measurement group_id="O2" value="0.46" lower_limit="0.43" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon test was utilized to compare the three moments: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman Test</method>
            <method_desc>Friedman to compare: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance. Wilcoxon was applied to locate the differences</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman Test</method>
            <method_desc>Friedman to compare: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance. Wilcoxon was applied to locate the differences</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Peroxidation</title>
        <description>Thiobarbituric acid–reactive substances (TBARS) assay was used as an index of lipid peroxidation in erythrocytes, at three moments: baseline, aerobic and resistance exercise.</description>
        <time_frame>3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Group</title>
            <description>HIV infected persons</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Non HIV-infected persons</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Peroxidation</title>
          <description>Thiobarbituric acid–reactive substances (TBARS) assay was used as an index of lipid peroxidation in erythrocytes, at three moments: baseline, aerobic and resistance exercise.</description>
          <units>picomol of TBARS/mg protein</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.356" lower_limit="1.27" upper_limit="3.12"/>
                    <measurement group_id="O2" value="2.888" lower_limit="1.118" upper_limit="5.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aerobic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.328" lower_limit="0.909" upper_limit="2.922"/>
                    <measurement group_id="O2" value="4.164" lower_limit="2.763" upper_limit="6.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.348" lower_limit="0.917" upper_limit="3.794"/>
                    <measurement group_id="O2" value="3.205" lower_limit="1.753" upper_limit="6.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon test was utilized to compare the three moments: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman Test</method>
            <method_desc>Friedman to compare: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance. Wilcoxon was applied to locate the differences</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman Test</method>
            <method_desc>Friedman to compare: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance. Wilcoxon was applied to locate the differences</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T CD4</title>
        <description>T CD4 lymphocytes counts at three moments: baseline, aerobic and resistance exercise.</description>
        <time_frame>3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Group</title>
            <description>HIV infected persons</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Non HIV-infected persons</description>
          </group>
        </group_list>
        <measure>
          <title>T CD4</title>
          <description>T CD4 lymphocytes counts at three moments: baseline, aerobic and resistance exercise.</description>
          <units>Cell/ul of blood</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417" lower_limit="116" upper_limit="1132"/>
                    <measurement group_id="O2" value="984" lower_limit="594" upper_limit="2145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aerobic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428" lower_limit="70" upper_limit="811"/>
                    <measurement group_id="O2" value="968" lower_limit="553" upper_limit="1387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378" lower_limit="70" upper_limit="981"/>
                    <measurement group_id="O2" value="974" lower_limit="643" upper_limit="1411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon test was utilized to compare the three moments: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman Test</method>
            <method_desc>Friedman to compare: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance. Wilcoxon was applied to locate the differences</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman Test</method>
            <method_desc>Friedman to compare: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance. Wilcoxon was applied to locate the differences</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophil Count</title>
        <description>Neutrophil count at three moments: baseline, aerobic and resistance exercise.</description>
        <time_frame>3 times - baseline (before the peak oxygen uptake test), aerobic (immediately after aerobic exercise) and resistance (immediately after resistance exercise).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Group</title>
            <description>HIV infected persons</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Non HIV-infected persons</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophil Count</title>
          <description>Neutrophil count at three moments: baseline, aerobic and resistance exercise.</description>
          <units>Cell/ul of blood</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3,237" lower_limit="1,901" upper_limit="4,207"/>
                    <measurement group_id="O2" value="3,212" lower_limit="2,328" upper_limit="4,174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aerobic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3,285" lower_limit="1,610" upper_limit="5,476"/>
                    <measurement group_id="O2" value="3,476" lower_limit="2,184" upper_limit="9,236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3,511" lower_limit="1,531" upper_limit="5,977"/>
                    <measurement group_id="O2" value="3,563" lower_limit="2,422" upper_limit="9,214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon test was utilized to compare the three moments: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman Test</method>
            <method_desc>Friedman to compare: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance. Wilcoxon was applied to locate the differences</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Friedman Test</method>
            <method_desc>Friedman to compare: baseline vs. aerobic, baseline vs. resistance and aerobic vs. resistance. Wilcoxon was applied to locate the differences</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Oxygen Uptake</title>
        <description>Is the maximum capacity of an individual's body to transport and utilize oxygen during incremental exercise.</description>
        <time_frame>1 time, before the exercise protocol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Group</title>
            <description>HIV infected persons</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Non HIV-infected persons</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Oxygen Uptake</title>
          <description>Is the maximum capacity of an individual's body to transport and utilize oxygen during incremental exercise.</description>
          <units>ml/min</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1,673" spread="349"/>
                    <measurement group_id="O2" value="2,167" spread="597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test was utilized to compare the two groups (HIV group and Control group)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pedro Dall'Ago</name_or_title>
      <organization>Hospital de Clínicas de Porto Alegre</organization>
      <phone>555133038751</phone>
      <email>pdallago@pq.cnpq.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

